



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Correspondence

SARS CoV-2 vaccine AND rituximab. Comment on: “SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response” by Verhoeven Joint Bone Spine. 2021;88:105258



ARTICLE INFO

Keywords:
SARS CoV-2
Vaccine
Rituximab

We would like to share ideas on “SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response [1]” Interrelationship between SARS CoV-2 vaccine AND rituximab is an interesting issue. For COVID-19, rituximab might induce sever outcome [2]. The similar process might be expected for COVID-19 vaccination. Timing might be important but it is largely unknown for “what is the best period for vaccination?” Based on present available data, at least 3-week period waiting after receiving rituximab is proven useful for improving immune response after COVID-19 vaccination [3]. Nevertheless, a recent report showed that rituximab did not preclude 2 vaccination since effective cellular immunity stimulation still exists [4].

Disclosure of interest

The authors declare that they have no competing interest.

References

- [1] Verhoeven F, Lepiller Q, Hecquet S, et al. SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response. *Joint Bone Spine* 2021;88:105258.
- [2] Daoussi D, Leonidou L, Kalogeropoulou C, et al. Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed. *Rheumatol Int* 2021;41:1839–43.
- [3] Perry C, Luttwak E, Balaban R, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. *Blood Adv* 2021;5:3053–61.
- [4] Benucci M, Damiani A, Infantino M, et al. Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab. *Immunol Res* 2021;69:309–11.

Rujittika Mungmunpantipantip^{a,*}

Viroj Wiwanitkit^b

^a Private Academic Consultant, Bangkok, Thailand

^b Honorary professor, Dr DY Patil University, Pune, India

* Corresponding author.

E-mail address: rujittika@gmail.com

(R. Mungmunpantipantip)

Accepted 21 September 2021
Available online 29 September 2021